Companies Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals (CRVS): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Corvus Pharmaceuticals, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,321,351FY2023
- $3,073,170FY2024
- $7,031,566FY2025
CEO total pay was $7,031,566 in fiscal 2025, up from $3,073,170 in fiscal 2024.
FY2025: salary $36,566 · bonus $0 · stock awards $0 · option awards $6,989,000
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Richard Miller | $36,566 | $0 | $0 | $6,989,000 | $0 | — | $6,000 | $7,031,566 |
| President and Chief Executive Officer | ||||||||
| Leiv Lea | 405,948 | 0 | 0 | 2,795,600 | 0 | — | 6,000 | 3,207,548 |
| Chief Financial Officer | ||||||||
| William Jones | 360,115 | 0 | 0 | 2,795,600 | 0 | — | 6,000 | 3,161,715 |
| Senior Vice President, Pharmaceutical Development | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Richard Miller | $7,031,566 | $3,073,170 | $1,321,351 | ↑ +3,958,396 |
| Leiv Lea | 3,207,548 | 1,614,453 | 660,764 | ↑ +1,593,095 |
| William Jones | 3,161,715 | 1,569,895 | 616,256 | ↑ +1,591,820 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation program is designed to provide a fixed base salary reflecting the executive's skill set, experience, role, and responsibilities, along with eligibility for discretionary annual performance-based bonuses and equity awards to incentivize employees in accordance with company policies.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Leiv Lea | Option | 26,666 | 0.97 | — |
| William Jones | Option | 26,666 | 0.97 | — |
| Richard Miller | Option | 53,333 | 0.97 | — |
| Richard Miller | Option | 66,666 | 0.91 | — |
| Leiv Lea | Option | 66,666 | 1.64 | — |
| William Jones | Option | 66,666 | 1.64 | — |
| Richard Miller | Option | 166,666 | 1.64 | — |
| Leiv Lea | Option | 200,000 | 4.99 | — |
| William Jones | Option | 200,000 | 4.99 | — |
| Leiv Lea | Option | 400,000 | 8.81 | — |
| William Jones | Option | 400,000 | 8.81 | — |
| Richard Miller | Option | 500,000 | 4.99 | — |
| Richard Miller | Option | 1,000,000 | 8.81 | — |
| William Jones | RSU | 3,407,335 | — | 17,435,512 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| David S. MooreIndependent · Audit · Compensation · Nominating and Corporate Governance | $11,250 | $0 | $170,988 | — | — | $182,238 |
| Scott W. MorrisonIndependent · Audit · Compensation | 61,000 | 0 | 50,472 | — | — | 111,472 |
| Richard van den BroekIndependent · Audit · Nominating and Corporate Governance (Chair) · Compensation | 36,808 | 0 | 68,844 | — | — | 105,652 |
| Linda S. Grais, M.D., J.DIndependent · Audit · Compensation · Nominating and Corporate Governance | 49,000 | 0 | 50,472 | — | — | 99,472 |
| Peter A. Thompson, M.DIndependent · Compensation · Nominating and Corporate Governance | 47,000 | 0 | 50,472 | — | — | 97,472 |
| Ian T. ClarkIndependent · Compensation · Nominating and Corporate Governance | 45,000 | 0 | 50,472 | — | — | 95,472 |
| Elisha P. (Terry) Gould IIIIndependent · Audit · Departed during FY | 24,316 | 0 | 0 | — | — | 24,316 |
| Richard A. Miller, M.DEmployee director · Board Chair · Compensation (Chair) · Nominating and Corporate Governance | — | — | — | — | — | 0 |
| Andrew C. Chan, M.D., Ph.DIndependent · Nominating and Corporate Governance · Newly elected | 0 | 0 | 0 | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $35,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 12,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $274,374 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $274,374 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Corvus Pharmaceuticals as a peer
Companies that benchmark against CRVS
3 companies name CRVS as a compensation peer
- Cardiff Oncology, Inc.CRDFFY2025
- Cartesian Therapeutics, Inc.RNACFY2025
- NEKTAR THERAPEUTICSNKTRFY2025
- SELLAS Life Sciences Group, Inc.SLSFY2025
Each company listed discloses CRVS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CRVS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Corvus Pharmaceuticals, Inc. | 2025 | Richard Miller | $36,566 | $0 | $6,989,000 | $0 | $7,031,566 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | 58,936,532 | 1,971,370 | 64,329 | 96.76% | Passed |
| 2025 | 2025-06-12 | 37,113,137 | 2,096,601 | 63,815 | 94.65% | Passed |
| 2024 | 2024-06-13 | 24,424,413 | 413,670 | 234,233 | 97.42% | Passed |
| 2023 | 2023-06-15 | 25,550,695 | 348,929 | 177,941 | 98.65% | Passed |
| 2022 | 2022-06-15 | 22,614,704 | 409,961 | 67,644 | 98.22% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-11 | 96.76%a |
| 2025 | 2025-06-12 | 94.65%b |
| 2024 | 2024-06-13 | 97.42%c |
a. Approved under the standard stated in the filing — “● For Proposal 3, the non-binding advisory vote to approve the compensation of our named executive officers, the proposal must receive a "For" vote from the majority of the votes cast, with votes cast excluding abstentions and broker non-votes.”.
b. Approved under the standard stated in the filing — “● For Proposal 3, the non-binding advisory vote to approve the compensation of our named executive officers, the proposal must receive a "For" vote from the majority of the votes cast, with votes cast excluding abstentions and broker non-votes.”.
c. Approved under the standard stated in the filing — “Approval, on a non-binding, advisory basis, of the compensation of our named executive officers pursuant to the compensation disclosure rules of the SEC, requires the affirmative vote of the majority of shares of common stock present online live or represented by proxy at the Annual Meeting and entitled to vote on such proposal. || Abstentions will have the same effect as an "Against" vote for purposes of determining whether this matter has been approved.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Richard Miller | Director | 2026-05-18 | A | 1,932 | $12 | $23,203 | Common | Form 4 ↗ |
| Richard Miller | Director | 2026-05-18 | A | 5,000 | 12 | 60,250 | Common | Form 4 ↗ |
| van den Broek Richard | Director | 2026-06-11 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter A. Thompson | Director | 2026-06-11 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Linda Grais | Director | 2026-06-11 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ian T. Clark | Director | 2026-06-11 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Moore | Director | 2026-06-11 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David S. Moore | Director | 2026-06-11 | A | 21,700 | 12 | 250,236 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (26 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Richard Miller. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · page 26. As printed: 7,031,566. View filing ↗
- Section 01, Leiv Lea. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · page 26. As printed: 3,207,548. View filing ↗
- Section 01, William Jones. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · page 26. As printed: 3,161,715. View filing ↗
- Section 08, David S. Moore. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 182,238. View filing ↗
- Section 08, Scott W. Morrison. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 111,472. View filing ↗
- Section 08, Richard van den Broek. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 105,652. View filing ↗
- Section 08, Linda S. Grais, M.D., J.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 99,472. View filing ↗
- Section 08, Peter A. Thompson, M.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 97,472. View filing ↗
- Section 08, Ian T. Clark. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 95,472. View filing ↗
- Section 08, Elisha P. (Terry) Gould III. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 24,316. View filing ↗
- Section 08, Richard A. Miller, M.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Andrew C. Chan, M.D., Ph.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Richard Miller 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Miller 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, van den Broek Richard 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter A. Thompson 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Linda Grais 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ian T. Clark 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Moore 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David S. Moore 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-12. Item 5.07 · say-on-pay result. As reported: 96.76% (votes for as printed: 58,936,532). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-13. Item 5.07 · say-on-pay result. As reported: 94.65% (votes for as printed: 37,113,137). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-14. Item 5.07 · say-on-pay result. As reported: 97.42% (votes for as printed: 24,424,413). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 274,374 + equity 0 + all other 0 = 274,374, summed across the director compensation table rows.
- Corvus Pharmaceuticals, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Corvus Pharmaceuticals, Inc.'s own proxy. As printed: 7,031,566. View filing ↗